TNF and early-onset autosomal dominant Alzheimer disease: Consequently, directly targeting these aggregates and reducing the levels of TNF and other inflammatory cytokines are both potential therapeutic targets for slowing Alzheimer’s disease pathogenesis and may be more effective when used in combination.